Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Safety, Tolerability, and Pharmacokinetics of Supratherapeutic Doses of ALG-000184 (Parts A and B) and the Absorption, Metabolism, Excretion, and Absolute Bioavailability of ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)

11 november 2026 bijgewerkt door: Aligos Therapeutics

A Phase 1 Trial in Healthy Participants to Evaluate Single and Multiple Oral Dose Safety, Tolerability, and Pharmacokinetics of Supratherapeutic Doses of ALG-000184 (Parts A and B) and the Absorption, Metabolism, Excretion, and Absolute Bioavailability of ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)

A Phase 1 trial of ALG-000184 in healthy participants to assess the safety and tolerability of single and multiple (if applicable) oral doses of ALG-000184 (Part A and B) and ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Geschat)

55

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: Aligos Therapeutics
  • Telefoonnummer: 800-466-6059
  • E-mail: info@aligos.com

Studie Locaties

    • Wisconsin
      • Madison, Wisconsin, Verenigde Staten, 53704
        • Aligos Investigational Site
        • Contact:
          • Aligos Investigational Site
          • Telefoonnummer: 800-466-6059
          • E-mail: info@aligos.com

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 60 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria: Key Inclusion Criteria

  1. Parts A and B only: Male or female between 18 and 60 years of age
  2. Part C only: Males between 18 and 55 years of age.
  3. Body mass index between 18.0 kg/m2 and 32.0 kg/m2
  4. In good health, as determined by no clinically significant findings from medical history, 12-lead ECG and vital signs measurements, and clinical laboratory assessments.
  5. Part C only: History of a minimum of 1 bowel movement per day.

Exclusion Criteria: Key Exclusion Criteria:

  1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).

  2. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator (or designee).

  3. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs.

  4. Confirmed systolic blood pressure >140 or <90 mmHg, diastolic blood pressure >90 or <50 mmHg, or pulse rate >100 or <40 beats per minute.

  5. Positive hepatitis panel and/or positive human immunodeficiency virus test.

  6. Parts A and B only: Any of the following at screening or check-in:

    1. QTcF >450 ms in males or >470 ms in females
    2. QRS duration >120 ms
    3. PR interval >210 ms
    4. findings which would make QTc measurements difficult or QTc data uninterpretable
  7. Administration of any vaccine within 30 days prior to dosing.

  8. Use or intend to use any prescription medications/products, other than hormone replacement therapy, within 14 days prior to dosing

  9. Alcohol consumption of >21 units per week for males and >14 units per week for females, as applicable.

  10. Positive urine drug screen at screening or positive alcohol test result or positive urine drug screen at check-in.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: ALG-000184

Oral tablet(s) of placebo in HV participants once daily for up to 10 days

Single or multiple doses of ALG-000184

Placebo-vergelijker: Placebo

Oral tablet(s) of placebo in HV participants once daily for up to 10 days

Single or multiple doses of Placebo

Ander: [14C]ALG-000184

Single oral dose of [14C]ALG-000184

Single micodose of [13C7,15N1]ALG-001075 with combination of [14C]ALG-000184

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Safety and Tolerability (Part A and B)
Tijdsspanne: From enrollment to end of treatment at 10 days

Number of participants with Incidence and severity of adverse events, 12-lead electrocardiogram parameters, and abnormal clinical laboratory results

From enrollment to end of treatment at 10 days
PK Parameters (Part A and B)
Tijdsspanne: From enrollment to end of treatment at 10 days

PK parameters of ALG-001075 and ALG-000302, including AUC0-∞

From enrollment to end of treatment at 10 days
PK Parameters (Part A and B)
Tijdsspanne: From enrollment to end of treatment at 10 days

PK parameters of ALG-001075 and ALG-000302, including AUC0-tlast

From enrollment to end of treatment at 10 days
PK Parameters (Part A and B)
Tijdsspanne: From enrollment to end of treatment at 10 days

PK parameters of ALG-001075 and ALG-000302, including AUC0-τ

From enrollment to end of treatment at 10 days
PK Parameters (Part A and B)
Tijdsspanne: From enrollment to end of treatment at 10 days

PK parameters of ALG-001075 and ALG-000302, including Cmax

From enrollment to end of treatment at 10 days
PK Parameters (Part A and B)
Tijdsspanne: From enrollment to end of treatment at 10 days

PK parameters of ALG-001075 and ALG-000302, including tmax t1/2

From enrollment to end of treatment at 10 days
PK Parameters (Part A and B)
Tijdsspanne: From enrollment to end of treatment at 10 days

PK parameters of ALG-001075 and ALG-000302, including ARAUC

From enrollment to end of treatment at 10 days
Total radioactivity recovery (fet1-t2) in urine and feces (Part C)
Tijdsspanne: From enrollment to end of treatment at 10 days

determine the routes, rates of elimination, and mass balance of total radioactivity following a single oral dose of [14C]ALG-000184

From enrollment to end of treatment at 10 days
Metabolic profiles of ALG-000184 (Part C)
Tijdsspanne: From enrollment to end of treatment at 10 days

Determine, where possible, the metabolite profiles in plasma, urine, and feces following administration of [14C]ALG-000184

From enrollment to end of treatment at 10 days
Identification of ALG-000184 (Part C)
Tijdsspanne: From enrollment to end of treatment at 10 days

Determine, where possible, the chemical structure of major metabolites in plasma, urine, and feces following administration of [14C]ALG-000184

From enrollment to end of treatment at 10 days
Bioavailability of ALG-001075 (Part C)
Tijdsspanne: From enrollment to end of treatment at 10 days

Determine the absolute bioavailability of ALG-001075 following oral administration of [14C]ALG-000184 relative to IV administration of [13C7,15N1]ALG-001075

From enrollment to end of treatment at 10 days
PK parameters (Part C)
Tijdsspanne: From enrollment to end of treatment at 10 days

PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including AUC0-∞

From enrollment to end of treatment at 10 days
PK parameters (Part C)
Tijdsspanne: From enrollment to end of treatment at 10 days

PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including AUC0-tlast

From enrollment to end of treatment at 10 days
PK parameters (Part C)
Tijdsspanne: From enrollment to end of treatment at 10 days

PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including Cmax

From enrollment to end of treatment at 10 days
PK parameters (Part C)
Tijdsspanne: From enrollment to end of treatment at 10 days

PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including tmax

From enrollment to end of treatment at 10 days
PK parameters (Part C)
Tijdsspanne: From enrollment to end of treatment at 10 days

PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including t1/2

From enrollment to end of treatment at 10 days

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
QTc (Part A and B)
Tijdsspanne: From enrollment to end of treatment at 10 days

Evaluate the effect of single and multiple (if applicable) oral doses of ALG-000184 on QTc in healthy participants

From enrollment to end of treatment at 10 days
Safety and Tolerability (Part C)
Tijdsspanne: From enrollment to end of treatment at 10 days

Number of participants with Incidence and severity of adverse events, 12-lead electrocardiogram parameters, and abnormal clinical laboratory results

From enrollment to end of treatment at 10 days

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

14 december 2026

Primaire voltooiing (Geschat)

6 augustus 2027

Studie voltooiing (Geschat)

1 oktober 2027

Studieregistratiedata

Eerst ingediend

11 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

11 november 2026

Eerst geplaatst (Werkelijk)

17 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

17 november 2026

Laatste update ingediend die voldeed aan QC-criteria

11 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • ALG-000184-209

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .